Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||CD274 positive|
|Therapy||Cisplatin + Fluorouracil + Pembrolizumab|
|Indication/Tumor Type||gastroesophageal junction adenocarcinoma|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CD274 positive||gastroesophageal junction adenocarcinoma||sensitive||Cisplatin + Fluorouracil + Pembrolizumab||Guideline||Actionable||Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Platinol (cisplatin), is included in guidelines as preferred first-line therapy for patients with esophagogastric junction adenocarcinoma expressing PD-L1 (CD274, CPS>=10), and without ERBB2 (HER2) overexpression (category 1), and as first-line therapy for patients with PD-L1 expression (CD274, CPS <10) and without ERBB2 (HER2) overexpression (category 2B) (NCCN.org).||detail...|
|CD274 positive||gastroesophageal junction adenocarcinoma||sensitive||Cisplatin + Fluorouracil + Pembrolizumab||Phase III||Actionable||In a Phase III trial (KEYNOTE-590), addition of Keytruda (pembrolizumab) to cisplatin and fluorouracil significantly improved overall survival (13.5 vs 9.4 mo, HR=0.62, p<0.0001) and progression-free survival (7.5 vs 5.5 mo, HR=0.51, p<0.0001) in patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma expressing PD-L1 (CPS>=10) (Ann Oncol. 31, no. 4_suppl (Sep 2020) S1192-S1193; NCT03189719).||detail...|
|PubMed Id||Reference Title||Details|
|LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study||Full reference...|